Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Fresenius Medical Care named Shervin Korangy as CEO Posted 10-22-2026
- Aligning Clinical Excellence with Health System Goals Through PD in Value-Based Models Posted 10-22-2026
- Update on National Institutes of Health websites Posted 10-22-2026
- What to Know About the American Society of Nephrology Kidney Week Posted 10-22-2026

